Details of Disease

General Information of Disease (ID: DISY2IPA)

• Disease Name: Tauopathy
• Disease Class: 6D80-6D8Z: Dementia
• Definition: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (tau proteins) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with alzheimer disease; dementia; parkinsonian disorders; progressive supranuclear palsy (supranuclear palsy, progressive); and corticobasal degeneration.
• Disease Hierarchy:
  DISM20FF: Neurodegenerative disease
  DISY2IPA: Tauopathy
• ICD Code: ICD-11: ICD-11: 6D85.Y
• Disease Identifiers:
  MONDO ID: MONDO_0005574
  MESH ID: D024801
  UMLS CUI: C0949664
  MedGen ID: 181880

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS-241027	DM6GB6B	Phase 1	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 30 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APP	TTE4KHA	Limited	Genetic Variation	[2]
BACE1	TTJUNZF	Limited	Biomarker	[3]
CAPN2	TTG5QB7	Limited	Biomarker	[4]
CDK5	TTL4Q97	Limited	Genetic Variation	[5]
CYP46A1	TT4EB85	Limited	Biomarker	[6]
NUAK1	TT65FL0	Limited	Biomarker	[7]
TARDBP	TT9RZ03	Limited	Biomarker	[8]
GABRG2	TT06RH5	moderate	Biomarker	[9]
GSK3B	TTRSMW9	moderate	Biomarker	[10]
TREM2	TTQRMSJ	moderate	Biomarker	[11]
ALOX5	TTSJ6Q4	Strong	Altered Expression	[12]
C3AR1	TTI6B3F	Strong	Biomarker	[13]
C9orf72	TTA4SHR	Strong	Biomarker	[14]
CX3CR1	TT2T98G	Strong	Biomarker	[15]
DLG4	TT9PB26	Strong	Biomarker	[16]
DYRK1A	TTSBVFO	Strong	Posttranslational Modification	[17]
EIF2AK3	TT79U1M	Strong	Biomarker	[18]
FKBP4	TTHY0FT	Strong	Genetic Variation	[19]
GGT1	TTZVT7O	Strong	Biomarker	[20]
HSPA8	TTMQL3K	Strong	Altered Expression	[21]
LRRK2	TTK0FEA	Strong	Genetic Variation	[22]
MAPK9	TT3IVG2	Strong	Biomarker	[23]
MSMB	TTYH1ZK	Strong	Genetic Variation	[24]
PIN1	TTJNTSI	Strong	Genetic Variation	[25]
PPME1	TTXQ54R	Strong	Biomarker	[26]
PRNP	TTY5F9C	Strong	Biomarker	[27]
SRPK2	TTCZEJ9	Strong	Biomarker	[28]
TTBK1	TTYFAM9	Strong	Biomarker	[29]
USP13	TTVJIO2	Strong	Biomarker	[30]
USP2	TTUEQ1W	Strong	Biomarker	[31]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC32A1	DTXQYLR	Limited	Biomarker	[32]
SLC26A7	DTOTME4	Strong	Biomarker	[33]

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NMNAT2	DE2HB58	Disputed	Biomarker	[34]
NMNAT1	DE4D159	Strong	Altered Expression	[35]
PARK7	DEPOVCH	Strong	Biomarker	[36]

This Disease Is Related to 57 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CETN1	OTGQ8JOZ	Limited	Biomarker	[37]
DNAJC5	OTCZDXAL	Limited	Genetic Variation	[38]
DUSP26	OTI7WIYN	Limited	Genetic Variation	[39]
EIF2A	OTWXELQP	Limited	Biomarker	[40]
LGI1	OTPS77HO	Limited	Biomarker	[41]
MARK4	OT6Z2TGV	Limited	Biomarker	[42]
NRXN3	OTJ0I7HJ	Limited	Genetic Variation	[41]
PHF6	OT8DXI40	Limited	Biomarker	[43]
PRLH	OTJBP360	Limited	Biomarker	[44]
PTBP2	OTF4S7NE	Limited	Biomarker	[45]
RBM4	OT5SFQA3	Limited	Altered Expression	[46]
REG1A	OTMHUH1D	Limited	Genetic Variation	[24]
SDF4	OTQ7WFYW	Limited	Biomarker	[37]
SFPQ	OTLCIAPJ	Limited	Biomarker	[47]
TESC	OTI8C76M	Limited	Biomarker	[48]
TIA1	OTGPN3P8	Limited	Biomarker	[49]
TRA2B	OTZYQW52	Limited	Biomarker	[50]
TTBK2	OT90YSM5	Limited	Biomarker	[29]
DCTN1	OT5B51FJ	Disputed	Genetic Variation	[51]
ADNP	OTEGICWR	Strong	Genetic Variation	[52]
BIN1	OTK8O0X8	Strong	Genetic Variation	[53]
BPIFA2	OTLFSDZD	Strong	Genetic Variation	[24]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[54]
EFHD2	OTM9VMN3	Strong	Biomarker	[55]
HSPH1	OTVRR73T	Strong	Altered Expression	[56]
IGLON5	OTB94PY2	Strong	Biomarker	[57]
INPP5K	OTQFLQKA	Strong	Altered Expression	[58]
LCMT1	OTRJQ16X	Strong	Genetic Variation	[26]
MID1	OTWN1PGU	Strong	Biomarker	[59]
MPHOSPH6	OT6E2S48	Strong	Biomarker	[60]
NECTIN3	OTS8N7MK	Strong	Biomarker	[61]
NPC1	OTRIPICX	Strong	Biomarker	[62]
OGA	OT7ZBWT1	Strong	Biomarker	[63]
OGT	OT1Z1ZXE	Strong	Biomarker	[64]
OPN1MW	OTPJ7LX4	Strong	Genetic Variation	[65]
OTUB1	OT8WWM9O	Strong	Biomarker	[66]
PDC	OT1UUVYY	Strong	Biomarker	[67]
PLEKHM2	OT4ZYV73	Strong	Altered Expression	[58]
PLP1	OT8CM9CX	Strong	Biomarker	[24]
PSPH	OTV1PVAX	Strong	Genetic Variation	[24]
PSPN	OT54LLZJ	Strong	Genetic Variation	[24]
PTPA	OTRGFOI7	Strong	Biomarker	[68]
RANBP9	OTM8COM5	Strong	Genetic Variation	[69]
RIDA	OTW4098I	Strong	Genetic Variation	[24]
RMDN1	OTE1NB6U	Strong	Biomarker	[70]
RMDN2	OTK5WSFI	Strong	Biomarker	[70]
RMDN3	OTKO7AUM	Strong	Biomarker	[70]
RNF213	OT4OVE9O	Strong	Genetic Variation	[71]
SCRN1	OTELM5C2	Strong	Biomarker	[72]
SGSM3	OTIB1P8A	Strong	Biomarker	[73]
SNW1	OTKWG3PS	Strong	Altered Expression	[58]
SPHKAP	OT5RHUYJ	Strong	Altered Expression	[58]
SRSF2	OTVDHO6U	Strong	Biomarker	[74]
STH	OTK8ULTH	Strong	Genetic Variation	[75]
STXBP3	OTTTYMAQ	Strong	Genetic Variation	[24]
SYBU	OT3FQV7N	Strong	Biomarker	[70]
SYNJ1	OTTE02XC	Strong	Genetic Variation	[76]

References

• [1] ClinicalTrials.gov (NCT01492374) Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease. U.S. National Institutes of Health.
• [2] The sterol regulatory element-binding protein 2 is dysregulated by tau alterations in Alzheimer disease.Brain Pathol. 2019 Jul;29(4):530-543. doi: 10.1111/bpa.12691. Epub 2019 Jan 28.
• [3] cPLA2 and desaturases underlie the tau hyperphosphorylation offset induced by BACE knock-down in neuronal primary cultures.Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3696-3707. doi: 10.1016/j.bbadis.2018.08.028. Epub 2018 Aug 24.
• [4] P301L tauopathy: confocal immunofluorescence study of perinuclear aggregation of the mutated protein.J Neurol Sci. 2002 Aug 15;200(1-2):85-93. doi: 10.1016/s0022-510x(02)00150-8.
• [5] Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.J Neurosci. 2017 Oct 11;37(41):9917-9924. doi: 10.1523/JNEUROSCI.0621-17.2017. Epub 2017 Sep 14.
• [6] Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology.Hum Mol Genet. 2015 Nov 1;24(21):5965-76. doi: 10.1093/hmg/ddv268. Epub 2015 Sep 10.
• [7] Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.Neuron. 2016 Oct 19;92(2):407-418. doi: 10.1016/j.neuron.2016.09.022. Epub 2016 Oct 6.
• [8] Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy.Neurosci Bull. 2019 Apr;35(2):183-192. doi: 10.1007/s12264-018-0300-0. Epub 2018 Oct 31.
• [9] Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP.Transl Psychiatry. 2018 Dec 13;8(1):265. doi: 10.1038/s41398-018-0319-z.
• [10] Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice.Neurotoxicology. 2016 Mar;53:290-300. doi: 10.1016/j.neuro.2016.02.012. Epub 2016 Mar 2.
• [11] Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model.Brain. 2018 Feb 1;141(2):422-458. doi: 10.1093/brain/awx350.
• [12] Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.Aging Cell. 2018 Jun;17(3):e12759. doi: 10.1111/acel.12759. Epub 2018 Apr 1.
• [13] Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer's Disease.Neuron. 2018 Dec 19;100(6):1337-1353.e5. doi: 10.1016/j.neuron.2018.10.031. Epub 2018 Nov 8.
• [14] No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease.Neuropathol Appl Neurobiol. 2014 Dec;40(7):844-54. doi: 10.1111/nan.12155.
• [15] CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies.Redox Biol. 2019 Apr;22:101118. doi: 10.1016/j.redox.2019.101118. Epub 2019 Feb 6.
• [16] Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration.Mol Neurobiol. 2018 Dec;55(12):9328-9333. doi: 10.1007/s12035-018-1079-8. Epub 2018 Apr 18.
• [17] Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis. 2005 Nov;20(2):392-400.
• [18] Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau.Nat Commun. 2019 Sep 30;10(1):4443. doi: 10.1038/s41467-019-12070-3.
• [19] Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy.Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4584-9. doi: 10.1073/pnas.1402645111. Epub 2014 Mar 12.
• [20] Relevance of host tau in tau seeding and spreading in tauopathies.Brain Pathol. 2020 Mar;30(2):298-318. doi: 10.1111/bpa.12778. Epub 2019 Aug 27.
• [21] Imbalance of Hsp70 family variants fosters tau accumulation.FASEB J. 2013 Apr;27(4):1450-9. doi: 10.1096/fj.12-220889. Epub 2012 Dec 27.
• [22] G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.Hum Mol Genet. 2018 Jan 1;27(1):120-134. doi: 10.1093/hmg/ddx389.
• [23] Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.Curr Alzheimer Res. 2005 Jan;2(1):3-18. doi: 10.2174/1567205052772713.
• [24] Involvement of Oligodendrocytes in Tau Seeding and Spreading in Tauopathies.Front Aging Neurosci. 2019 May 28;11:112. doi: 10.3389/fnagi.2019.00112. eCollection 2019.
• [25] Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.J Clin Invest. 2008 May;118(5):1877-89. doi: 10.1172/JCI34308.
• [26] Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110.
• [27] Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.JAMA Neurol. 2019 Oct 1;76(10):1219-1229. doi: 10.1001/jamaneurol.2019.2050.
• [28] Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies.J Exp Med. 2018 Dec 3;215(12):3038-3056. doi: 10.1084/jem.20180539. Epub 2018 Oct 29.
• [29] Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.Mol Neurodegener. 2018 Feb 6;13(1):7. doi: 10.1186/s13024-018-0237-9.
• [30] Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer's Disease.J Alzheimers Dis. 2019;72(2):425-441. doi: 10.3233/JAD-190635.
• [31] Gender-Specific Expression of Ubiquitin-Specific Peptidase 9 Modulates Tau Expression and Phosphorylation: Possible Implications for Tauopathies.Mol Neurobiol. 2017 Dec;54(10):7979-7993. doi: 10.1007/s12035-016-0299-z. Epub 2016 Nov 23.
• [32] Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice.Mol Ther. 2017 Jan 4;25(1):140-152. doi: 10.1016/j.ymthe.2016.10.010. Epub 2017 Jan 4.
• [33] MSUT2 is a determinant of susceptibility to tau neurotoxicity.Hum Mol Genet. 2011 May 15;20(10):1989-99. doi: 10.1093/hmg/ddr079. Epub 2011 Feb 25.
• [34] CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.Hum Mol Genet. 2012 Jan 15;21(2):251-67. doi: 10.1093/hmg/ddr492. Epub 2011 Oct 25.
• [35] NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.Behav Brain Res. 2018 Feb 26;339:140-152. doi: 10.1016/j.bbr.2017.11.030. Epub 2017 Nov 23.
• [36] Role of DJ-1 in Parkinson's disease.J Mol Neurosci. 2006;29(3):215-25. doi: 10.1385/jmn:29:3:215.
• [37] A novel calcium-binding protein is associated with tau proteins in tauopathy.J Neurochem. 2008 Jul;106(1):96-106. doi: 10.1111/j.1471-4159.2008.05339.x. Epub 2008 Jul 1.
• [38] Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator.EMBO Mol Med. 2018 Nov;10(11):e8587. doi: 10.15252/emmm.201708587.
• [39] Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.J Neurosci. 2018 Jan 3;38(1):74-92. doi: 10.1523/JNEUROSCI.1483-17.2017. Epub 2017 Nov 13.
• [40] PERK activation mitigates tau pathology invitro and invivo.EMBO Mol Med. 2017 Mar;9(3):371-384. doi: 10.15252/emmm.201606664.
• [41] Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.Physiol Rev. 2017 Apr;97(2):839-887. doi: 10.1152/physrev.00010.2016.
• [42] Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.Sci Rep. 2016 Oct 6;6:34784. doi: 10.1038/srep34784.
• [43] Disclosing the Mechanism of Spontaneous Aggregation and Template-Induced Misfolding of the Key Hexapeptide (PHF6) of Tau Protein Based on Molecular Dynamics Simulation.ACS Chem Neurosci. 2019 Dec 18;10(12):4810-4823. doi: 10.1021/acschemneuro.9b00488. Epub 2019 Nov 12.
• [44] Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.J Alzheimers Dis. 2018;62(4):1725-1736. doi: 10.3233/JAD-171041.
• [45] MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy.Hum Mol Genet. 2011 Oct 15;20(20):4016-24. doi: 10.1093/hmg/ddr330. Epub 2011 Aug 1.
• [46] RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion.J Biol Chem. 2006 Aug 25;281(34):24479-88. doi: 10.1074/jbc.M603971200. Epub 2006 Jun 15.
• [47] Dysregulation and Dislocation of SFPQ Disturbed DNA Organization in Alzheimer's Disease and Frontotemporal Dementia.J Alzheimers Dis. 2018;61(4):1311-1321. doi: 10.3233/JAD-170659.
• [48] Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.Brain Dev. 2015 Jun;37(6):553-62. doi: 10.1016/j.braindev.2014.08.010. Epub 2014 Oct 19.
• [49] TIA1 regulates the generation and response to toxic tau oligomers.Acta Neuropathol. 2019 Feb;137(2):259-277. doi: 10.1007/s00401-018-1937-5. Epub 2018 Nov 21.
• [50] Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta.J Biol Chem. 2003 May 23;278(21):18997-9007. doi: 10.1074/jbc.M301800200. Epub 2003 Mar 20.
• [51] DCTN1 F52L mutation case of Perry syndrome with progressive supranuclear palsy-like tauopathy.Parkinsonism Relat Disord. 2018 Jun;51:105-110. doi: 10.1016/j.parkreldis.2018.02.038. Epub 2018 Feb 23.
• [52] Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study.Mol Psychiatry. 2021 May;26(5):1619-1633. doi: 10.1038/s41380-019-0563-5. Epub 2019 Oct 30.
• [53] Structural Basis of Tau Interaction With BIN1 and Regulation by Tau Phosphorylation.Front Mol Neurosci. 2018 Nov 14;11:421. doi: 10.3389/fnmol.2018.00421. eCollection 2018.
• [54] NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.PLoS One. 2019 Mar 13;14(3):e0213666. doi: 10.1371/journal.pone.0213666. eCollection 2019.
• [55] Impact of Swiprosin-1/Efhd2 on Adult Hippocampal Neurogenesis.Stem Cell Reports. 2018 Feb 13;10(2):347-355. doi: 10.1016/j.stemcr.2017.12.010. Epub 2018 Jan 11.
• [56] Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.Mol Cell Biol. 2010 Oct;30(19):4626-43. doi: 10.1128/MCB.01493-09. Epub 2010 Aug 2.
• [57] Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.Brain. 2018 Jan 1;141(1):13-36. doi: 10.1093/brain/awx189.
• [58] A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP.Front Cell Neurosci. 2019 Oct 1;13:435. doi: 10.3389/fncel.2019.00435. eCollection 2019.
• [59] Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.Sci Rep. 2017 Oct 23;7(1):13753. doi: 10.1038/s41598-017-12974-4.
• [60] Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.FASEB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub 2009 Apr 15.
• [61] Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy.PLoS One. 2014 Feb 3;9(2):e87605. doi: 10.1371/journal.pone.0087605. eCollection 2014.
• [62] Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis.Hum Mol Genet. 2009 Mar 1;18(5):956-65. doi: 10.1093/hmg/ddn423. Epub 2008 Dec 12.
• [63] Sugar Kick Prevents Memory Impairment.J Med Chem. 2019 Nov 27;62(22):10059-10061. doi: 10.1021/acs.jmedchem.9b01668. Epub 2019 Oct 31.
• [64] Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.Mol Neurodegener. 2017 May 18;12(1):39. doi: 10.1186/s13024-017-0181-0.
• [65] Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration.Acta Neuropathol. 2014 Feb;127(2):271-82. doi: 10.1007/s00401-013-1193-7.
• [66] Tau interactome mappingbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.Acta Neuropathol. 2017 May;133(5):731-749. doi: 10.1007/s00401-016-1663-9. Epub 2017 Jan 12.
• [67] Cerebrovascular inflammation is associated with tau pathology in Guam parkinsonism dementia.J Neural Transm (Vienna). 2018 Jul;125(7):1013-1025. doi: 10.1007/s00702-018-1883-3. Epub 2018 Apr 26.
• [68] Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.Neurosci Lett. 2019 Mar 23;696:179-183. doi: 10.1016/j.neulet.2018.12.034. Epub 2018 Dec 23.
• [69] Enhanced tau pathology via RanBP9 and Hsp90/Hsc70 chaperone complexes.Hum Mol Genet. 2017 Oct 15;26(20):3973-3988. doi: 10.1093/hmg/ddx284.
• [70] Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.ACS Chem Neurosci. 2019 Mar 20;10(3):1118-1120. doi: 10.1021/acschemneuro.9b00002. Epub 2019 Jan 18.
• [71] S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy.Transl Psychiatry. 2019 Jan 29;9(1):44. doi: 10.1038/s41398-019-0388-7.
• [72] Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.Acta Neuropathol Commun. 2019 Dec 3;7(1):195. doi: 10.1186/s40478-019-0848-6.
• [73] Loss of Tau results in defects in photoreceptor development and progressive neuronal degeneration in Drosophila.Dev Neurobiol. 2014 Dec;74(12):1210-25. doi: 10.1002/dneu.22199. Epub 2014 Jun 18.
• [74] SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.J Alzheimers Dis. 2018;61(2):561-570. doi: 10.3233/JAD-170418.
• [75] The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease.Neurosci Lett. 2003 Aug 28;347(3):143-6. doi: 10.1016/s0304-3940(03)00670-0.
• [76] SYNJ1 gene associated with neonatal onset of neurodegenerative disorder and intractable seizure.Mol Genet Genomic Med. 2018 Jan;6(1):109-113. doi: 10.1002/mgg3.341. Epub 2017 Nov 27.